Business
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence
About this update from Bioxcel Therapeutics, Inc.
[{"type":"text","content":"NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET. Vimal Mehta, Ph.D., Chief Executive Officer, and Vincent J. O’Neill, M.D., Chief R&D Officer, OnkosXcel Therapeutics, a wholly owned subsidiary of BioXcel Therapeutics, Inc., will be joined by a panel of leading oncology experts to review top-line Phase 2 data results being presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), and the development path and future opportunities for BXCL701, which is currently being developed for the potential treatment of small cell neuroendocrine prostate cancer (SCNC), an aggressive variant of prostate cancer. SCNC represents a rare, underserved, growing patient population, with SCNC cases increasing due to earlier and more widespread use of androgen receptor inhibitors. In 2022, there were an estimated 268,5001 new prostate cancer patients, with approximately 10,740 patients progressing to SCNC. Participating KOLs and discussion topics will include: Daniel P. Petrylak, M.D.: Prostate Cancer Overview and Challenges with Current Immuno-therapyDaniel P. Petrylak, M.D., is Professor of Medicine and Urology at Yale School of Medicine and a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney, and testicular cancer. At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research. Louis M. Weiner, M.D.: BXCL701 Mechanism of ActionDr. Louis M. Weiner is Director of Georgetown Lombardi Comprehensive Cancer Center, one of 53 National Cancer Institute (NC...